Brain tumors hijack circadian clock to grow
Glioblastoma is an aggressive, incurable brain cancer that is the most common malignant brain tumor in adults. New research from Washington University in St. Louis shows that glioblastoma has an internal clock and syncs its daily rhythms to match — and take advantage of — the rhythms of its host.
Analyzing multiple mammograms improves breast cancer risk prediction
A new, artificial intelligence-based method of analyzing mammograms, developed by researchers at WashU Medicine, identified individuals at high risk of developing breast cancer more accurately than the standard, questionnaire-based method did.
New drug tested to reduce side effect of ‘half-matched’ stem cell transplants
Results from a clinical trial conducted at WashU Medicine showed adding the investigational drug itacitinib to standard care for “half-matched” stem cell transplantation may reduce rates of graft-versus-host disease.
New cancer research reveals how fructose indirectly feeds tumors
WashU research shows that the liver turns fructose into lipids that many types of cancers crave.
Siteman Cancer Center’s new outpatient building named in honor of Gary C. Werths
Siteman Cancer Center’s new building for outpatient care will be named the Gary C. Werths Building. A transformative commitment by the late Werths and his husband, Richard Frimel, will support cancer research and medical student scholarships.
World leaders in ending blood cancer
The Siteman Blood Cancer Center delivers tomorrow’s treatments today.
Birthplace of precision medicine
At the forefront of individualized cancer care.
Mobilizing the best to start the fight earlier
Getting a head start on detection and treatment in adults under 50.
Probiotic delivers anticancer drug to the gut
Researchers at WashU Medicine engineered a yeast probiotic to deliver immunotherapy to the gut where it reduced gastrointestinal tumors in mice, offering a potentially novel strategy to target hard-to-reach gut cancers.
Vaccine shows promise against aggressive breast cancer
A small clinical trial conducted at WashU Medicine shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.
Older Stories